FDA Grants Epeius Biotechnologies' Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
Tue, 08 Jul 2008, 18:01:25 EST — Edited by Debra Tone
SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of all soft tissue sarcomas. This latest approval is the third clinical indication for which Rexin-G has been formally recognized by the FDA in the United States.

Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma RandD Summit Conference in Boston
Thu, 18 Oct 2007, 22:13:00 EST — Edited by Carly Zander
SAN MARINO, Calif. and BOSTON, Mass. - Oct. 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on 'The Advent of Pathotropic Medicine for Cancer' at the Global Pharma R&D Summit 2007 to be held in Boston.

California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System
Tue, 10 Jul 2007, 14:00:00 EST — Edited by Chris Simmons
SAN MARINO, Calif. - July 10 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world's first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers.

Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation
Mon, 18 Jun 2007, 23:36:00 EST — Edited by Chris Simmons
PASADENA, Calif. - June 18 (SEND2PRESS NEWSWIRE) -- Osmetech plc (LSE, AIM; OMH) today announced that it has granted a non-exclusive research license to Waltham, Massachusetts, US-based Minerva Biotechnologies Corporation ('Minerva') for use of Osmetech's self-assembling monolayer (SAM) technology in conjunction with Minerva's proprietary nanoparticle technology.

Mark Whitacre, Ph.D. Joins Management Team at Cypress Systems, Inc.
Wed, 13 Jun 2007, 14:15:00 EST — Edited by Chris Simmons
FRESNO, Calif. - June 13 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc, a Fresno CA based biotechnology company, announced that it has hired Mark Whitacre, Ph.D. Dr. Whitacre joined the executive management team effective January 1, 2007 as COO & President, Technology and Business Development, following the opening of a new office in Pensacola, Florida in December, 2006.

Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences
Tue, 15 May 2007, 14:00:00 EST — Edited by Chris Simmons
SAN MARINO, Calif. - May 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology embodied in its lead product, Rexin-G.

Rexin-G(TM), The World's First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer
Mon, 06 Nov 2006, 13:36:00 EST — Edited by Christopher Simmons
SAN MARINO, Calif. and MANILA, Philippines - Nov. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.

Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine
Wed, 11 Oct 2006, 16:18:00 EST — Edited by Christopher Simmons
SAN MARINO, Calif. - Oct. 11 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company's innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM).

Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development
Tue, 20 Jun 2006, 15:15:00 EST — Edited by Christopher L. Simmons
MALVERN, PA - June 20 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation (RBC) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC's DiscoveryDot(TM) nanoliter screening platform.

Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format
Thu, 01 Jun 2006, 05:12:00 EST — Edited by Christopher L. Simmons
CORNWALL, UK and MALVERN, PA - June 1 (SEND2PRESS NEWSWIRE) -- Key Organics Ltd and Reaction Biology Corporation today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for 'rental' screening on RBC's DiscoveryDot(TM) platform. For the first time, customers will be able to screen the Key library without having to purchase it outright.

Epeius Biotechnologies Establishes Corporate Headquarters in San Marino, California - Facilities Include a Clinical Research Unit Dedicated to Evaluating New Genetic Medicine for Cancer
Tue, 04 Apr 2006, 18:08:00 EST — Edited by Debra Tone
SAN MARINO, CA - Apr. 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the establishment of its main corporate headquarters in San Marino, California. The specialty pharmaceutical company has been granted Orphan Drug Status by the FDA for its lead product Rexin-G(TM), an innovative anti-cancer agent that seeks out and destroys metastatic disease. Rexin-G(TM) has been tested in a wide variety of cancer types, including pancreatic cancer, breast cancer, colon cancer, uterine cancer, laryngeal cancer, smooth muscle cancer (leiomyosarcoma) and skin cancer (malignant melanoma).

Reaction Biology Corp. Awarded Phase II SBIR Grant for Drug Discovery
Tue, 09 Aug 2005, 10:56:00 EST — Edited by Christopher Simmons
MALVERN, PA - August 9 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced that it has been awarded a Phase II SBIR grant from the National Institutes of Health to apply its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery.

Clinical Trial For Pancreatic Cancer Opens at Mayo Clinic Using Tumor-Targeted Gene Therapy Vector
Fri, 15 Jul 2005, 12:03:00 EST — Edited by Christopher Simmons
LOS ANGELES, Calif. - July 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, announced today that a Phase I clinical trial has opened at Mayo Clinic Cancer Center, Rochester, Minnesota to test the safety of Rexin-G(TM), the first tumor-targeted gene therapy vector to gain Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The clinical protocol has passed the rigorous reviews of the FDA, the NIH/Recombinant Advisory Committee, and the Institutional Review Board of Mayo Clinic.

Reaction Biology Corporation Awarded NIH Kinase Grant
Tue, 21 Jun 2005, 10:21:00 EST — Edited by Christopher Simmons
MALVERN, PA - June 21 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced that it has been awarded a Phase I SBIR grant from the National Institutes of Health to develop its new microarray kinase screening technology for testing compounds in nanoliter reactions.

Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector
Tue, 05 Apr 2005, 12:52:00 EST — Edited by Christopher Simmons
LOS ANGELES, Calif. -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer.